Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Uterine Cervical Neoplasms × atezolizumab × Clear all
NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Kymab Limited

Phase 1/2 Terminated
222 enrolled 49 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms